Treatment selection markers, sometimes called predictive markers, are factors that help clinicians select therapies that maximize good outcomes and minimize adverse outcomes for patients. Existing statistical methods for evaluating a treatment selection marker include assessing its prognostic value, evaluating treatment effects in patients with a restricted range of marker values, and testing for a statistical interaction between marker value and treatment. These methods are inadequate, because they give misleading measures of performance that do not answer key clinical questions about how the marker might help patients choose treatment, how treatment decisions should be made on the basis of a continuous marker measurement, what effect using the marker to select treatment would have on the population, or what proportion of patients would have treatment changes on the basis of marker measurement. Marker-by-treatment predictiveness curves are proposed as a more useful aid to answering these clinically relevant questions, because they illustrate treatment effects as a function of marker value, outcomes when using or not using the marker to select treatment, and the proportion of patients for whom treatment recommendations change after marker measurement. Randomized therapeutic clinical trials, in which entry criteria and treatment regimens are not restricted by the marker, are also proposed as the basis for constructing the curves and evaluating and comparing markers.
would have treatment changes on the basis of marker measurement. Marker-by-treatment predictiveness curves are proposed as a more useful aid to answering these clinically relevant questions, because they illustrate treatment effects as a function of marker value, outcomes when using or not using the marker to select treatment, and the proportion of patients for whom treatment recommendations change after marker measurement. Randomized therapeutic clinical trials, in which entry criteria and treatment regimens are not restricted by the marker, are also proposed as the basis for constructing the curves and evaluating and comparing markers. A dvances in our understanding of the molecular biology of disease and the mechanisms of treatment response, as well as increased facility in the genetic profiling of patients, have led to high hopes for personalized medicine. The identification and validation of treatment selection markers is a component of such personalized care. Treatment selection markers, sometimes called predictive markers, are factors that help clinicians select therapies that maximize good outcomes and minimize adverse outcomes for patients. These may be patient characteristics, clinical findings, test or imaging results, or any combination of these. An example of a successful treatment selection marker is KRAS gene expression in colorectal cancer tumors (1) . Patients without KRAS mutations have far better outcomes with antiepidermal growth factor receptor (EGFR) treatment than those with KRAS mutations, who derive essentially no benefit from it. This makes KRAS expression a useful marker for selecting treatment. The U.S. Food and Drug Administration labeling for 2 EGFR inhibitors, cetuximab and panitumumab, now states that these drugs are not recommended for the treatment of colorectal cancer in patients with KRAS mutations in codon 12 or 13. Whereas a KRAS mutation has a strong association with treatment response, other markers have weaker relationships, and appropriate measures are needed to quantify how well these markers perform.
Statistical methods for evaluating treatment selection markers are much less well developed than those for evaluating diagnostic and screening markers (2, 3) or prognostic and risk prediction markers (4 -7) . Here, we propose an approach to evaluating treatment selection markers and highlight the utility of our approach for comparing candidate markers.
CLINICAL EXAMPLE
The KRAS gene mutation so clearly distinguishes which patients will respond to EGFR treatment that it does not provide a useful example of the challenges of evaluating and comparing markers. Instead, we base our discussion on the clinical challenge of identifying women with breast cancer who will benefit from adjuvant chemotherapy. Most women with estrogen receptor-positive breast cancer who are node-positive or high-risk nodenegative routinely receive hormonal therapy (for example, with tamoxifen) and adjuvant chemotherapy, even though many believe that only a subset of these women actually benefit from the adjuvant chemotherapy (8) . If a marker could identify the subset of women who would benefit, the remaining women could avoid the unnecessary and potentially toxic chemotherapy, thereby reducing both adverse effects and the overall costs of treatment. An international survey (9) listed the development of a marker for identifying women who could be spared chemotherapy as the highest translational research priority in breast cancer.
A randomized trial (10) that compared tamoxifen alone to tamoxifen plus chemotherapy for the treatment of estrogen receptor-positive, node-positive breast cancer found that adjuvant chemotherapy improved outcomes overall: The 5-year disease-free survival (DFS) rate for tamoxifen plus chemotherapy was 79%, compared with 76% for tamoxifen alone. A subsequent analysis (11) in a subset of the trial participants found that a multigene tumor assay, the 21-gene recurrence score (Oncotype DX, Genomic Health, Redwood City, California), was useful for identifying the subset of women who would benefit from adjuvant chemotherapy.
To illustrate our approach to evaluating treatment selection markers, we simulated data for a similar trial of breast cancer treatment with 3000 participants, 1500 in each treatment group. The Appendix, available at www .annals.org, provides details of the simulation procedure. The 5-year DFS rates are identical to those in the actual trial (10) . The advantage of using simulated data over actual trial data is that we can use the simulation model to create markers that perform differently and then compare marker performance. We created 7 treatment selection markers (termed A, B, C, D, E, F, and G, with marker C constructed to perform similarly to the 21-gene recurrence score [11] ), and we use these to illustrate both current approaches to evaluating marker performance and our proposed approach.
MARKER-BY-TREATMENT PREDICTIVENESS CURVES
Our discussion relies on marker-by-treatment predictiveness curves, which we introduce as a useful visual aid for assessing marker performance. The curves (Figure) display response rates (5-year DFS in our example) as a function of the marker for each treatment group (tamoxifen plus chemotherapy or tamoxifen alone). Markers are shown on both a percentile scale, with the proportion of women with marker observations less than a given raw value noted, and on the scale of the raw marker value. Displaying marker percentiles facilitates comparing markers measured on different scales (for example, markers A and B in the Figure) by standardizing them to the same scale. Predictiveness curves were originally proposed for evaluating the prognostic capacity of a marker for patients who receive a given treatment (6, 7); here, we present a curve for each treatment. Displays similar to marker-bytreatment predictiveness curves have been used in the literature (11-13), but raw marker values are typically used instead of standardized percentile values.
CURRENT APPROACHES TO EVALUATING MARKER PERFORMANCE

Studies of a Single Treatment
A common first step in evaluating a candidate treatment selection marker is to study the ability of the marker to predict outcomes in a study of a single treatment (its prognostic value). However, knowing the prognostic value of the marker for patients receiving a single treatment does not tell us about its performance for treatment selection. Marker A might be considered a useful marker if it were measured only in women who received tamoxifen plus chemotherapy, because higher marker values are associated with higher DFS rates and lower marker values with lower DFS rates (Figure) . However, marker A is not useful for guiding treatment decisions, because the difference in DFS rates between the treatments is the same for all patients regardless of marker value. Because all participants receive the same benefit from adding adjuvant chemotherapy to tamoxifen therapy, the marker is not useful for choosing the best treatment.
In contrast, with combined therapy the DFS rate for marker B is the same at all marker values, which might make it seem not useful if it were measured only in women who received tamoxifen plus chemotherapy. However, because different treatment effects are seen at different marker values, marker B is useful for treatment selection. Patients with high marker values have higher DFS rates with adjuvant chemotherapy and should be considered candidates for it, whereas those with low marker values should not because they have lower DFS rates with adjuvant treatment. Data from a study of a single treatment do not yield useful information about the performance of a treatment selection marker; the outcomes under the treatments must be compared at each marker value.
Restricted Entry Trials
Another common approach to studying a treatment selection marker is to evaluate treatment efficacy in a randomized trial in which eligibility depends on marker value. In what is sometimes called an enrichment design (14, 15) , the enrolled patients (who are most commonly marker-
Key Summary Points
Treatment selection markers are clinical measures associated with effects of treatment. They help clinicians select one treatment over others to maximize good outcomes and minimize adverse outcomes for patients.
No standard way to evaluate treatment selection markers exists, and identifying useful markers can be difficult when the association between marker value and treatment response is modest.
Current approaches commonly used to evaluate treatment selection markers include assessing outcomes associated with the marker in a single treatment group, assessing treatment effects in a subset of patients with specific marker values, and testing for statistical interaction between the treatment and marker. These may provide misleading assessments of marker performance and assessments that are not clinically useful.
More clinically useful approaches to evaluating treatment selection markers involve visualizing treatment effect as a function of marker value by using treatment-by-marker predictiveness curves, comparing outcomes in the treated population when the marker is and is not used to select treatment, and assessing the proportion of patients for whom treatment recommendations change after marker measurement. The 5-year DFS rate is plotted as a function of marker percentile, with raw marker values shown in parentheses. The overall DFS rate with use of the marker for guiding treatment is shown, as well as the percentage of women who have higher DFS rates with tamoxifen alone (marker-negative). In the absence of the marker, chemotherapy would be recommended for all women (overall DFS rate, 79%). Markers A and D are prognostic but not useful for selecting treatment, because all patients are recommended chemotherapy regardless of marker value. Marker B is not prognostic on tamoxifen plus chemotherapy but is useful for selecting treatment. Marker C performs similarly to the 21-gene recurrence score, an existing treatment selection marker (11) . Marker D has the same interaction with treatment as marker C. Marker E is a very good marker for treatment selection. Marker F has the same association with response to each treatment as marker E, but a different distribution; marker F has a worse performance for treatment selection than marker E. DFS ϭ disease-free survival.
positive) are believed to be most likely to respond to the new treatment. This design is useful for determining whether a therapy is efficacious in the marker-defined subset of the population, but it does not provide useful information about whether the marker should be used to select treatment. For example, consider the DFS rates across the entire range of values for marker A (Figure) . A trial for which eligibility depended on a patient's value for marker A would find a positive treatment effect in any markerdefined subpopulation, because the DFS rate is always higher with the addition of chemotherapy. However, this does not imply that marker A should be used to guide treatment decisions, because marker A provides no information about whether adjuvant chemotherapy is or is not beneficial. To assess the performance of a treatment selection marker, participants with all marker values must be enrolled in the trial. As another example, before KRAS expression was identified as a useful marker for identifying patients with colorectal cancer who would benefit from anti-EGFR treatment, EGFR expression itself was thought to be a useful treatment selection marker. Only patients with positive EGFR expression were initially enrolled into clinical trials for anti-EGFR treatment (16) . However, later studies (17) found similar effects of anti-EGFR treatment in patients regardless of whether their tumors expressed EGFR by immunohistochemistry. This led to the understanding that EGFR expression is not a useful treatment selection marker and to guideline recommendations that it not be used for anti-EGFR treatment selection (18).
Testing for Interaction in Randomized Trials
The most common approach to evaluating a treatment selection marker is to assess whether the treatment effect in a randomized trial varies with marker value. In statistical terms, this is a test for an interaction between treatment assignment and marker value (14, 19 -22) , or a test of effect modification. The interaction quantifies how the treatment effect, often expressed as the difference in response rates between treatments (or the odds ratio or hazard ratio for the outcome with treatment), changes with marker value. A statistically significant interaction is often taken to indicate that the marker is useful for treatment selection.
Although Table  1 ]) but perform differently. Marker C, modeled after the 21-gene recurrence score, identifies some patients who have higher DFS rates with combined therapy and others who have higher DFS rates with tamoxifen alone, whereas the curves for marker D show a higher DFS rate with combined therapy for all patients. Knowing a woman's value for marker C therefore provides clinically useful information about whether she will benefit from adjuvant chemotherapy, whereas knowing her value for marker D does not, despite the identical statistical interactions.
Of note, the magnitude of the interaction also lacks a clinical interpretation-it does not describe how useful the marker measurement is to patients, or the population effect of using the marker to select treatment. We will revisit this point after proposing our alternative summaries of marker performance.
PROPOSED APPROACH TO EVALUATING MARKER PERFORMANCE
Our proposed approach to evaluating treatment selection markers addresses the previously described limitations. We focus on the setting of a randomized trial that compares 2 treatments and assume that the marker is measured at baseline in all trial patients. The marker may represent a single measurement or a combination of measurements (such as the 21-gene recurrence score). Both continuous markers (for which statistical methods are most lacking) and binary markers are discussed. The Appendix provides statistical details of our approach.
The first step is to plot marker-by-treatment predictiveness curves to illustrate information useful to individual patients and clinicians for making treatment decisions. For example, a woman with a marker E value of 12, at the 20th percentile, has a 96% (95% CI, 95% to 97%) chance of remaining alive and disease-free with tamoxifen alone, compared with a 58% (CI, 54% to 62%) chance with combined therapy. This would usually be sufficient indication that she avoid adjuvant chemotherapy, because it will not benefit her.
Defining Marker Positivity
In practice, the clinical task is to decide whether to treat a given patient, which requires a method for choosing treatment on the basis of the marker. A common strategy involves dichotomizing the marker at a chosen threshold. In our breast cancer example, women with values above DFS ϭ disease-free survival. * In the absence of marker measurement, all women would be recommended adjuvant chemotherapy, which is associated with a 5-year DFS rate of 79% (CI, 78% to 82%). † Percentage of women who have higher 5-year DFS rates with tamoxifen therapy alone; these women would be advised to forgo adjuvant chemotherapy after marker measurement. ‡ Increase in the log odds ratio for treatment per percentile increase in the marker. § Modeled after the 21-gene recurrence score (11) .
this threshold (marker-positive) would receive a recommendation for adjuvant chemotherapy, whereas those below the threshold (marker-negative) would receive a recommendation for tamoxifen alone. Identifying the marker threshold is key, and marker-by-treatment predictiveness curves can be helpful in this regard. One choice of threshold is the lowest marker value at which the DFS rate is higher with the addition of chemotherapy (the point where the 2 curves cross in the Figure) . If other factors, such as adverse effects or cost of adjuvant chemotherapy, necessitated that chemotherapy increase DFS by a set amount, then the threshold could be set to the point at which the DFS rate with chemotherapy is at least that amount higher than without chemotherapy. The marker threshold may also depend on the DFS rate with tamoxifen alone; if the rate is sufficiently high, adjuvant chemotherapy may not be warranted. Vickers and colleagues (23) formalize these principles and use a decision-making approach for choosing the marker threshold.
Response Rate Under Marker-Based Treatment Policy
Once a marker threshold is identified, marker-bytreatment predictiveness curves can be used to determine a key parameter relating to marker performance: The population effect of using the marker to select treatment (23, 24) . In our example, under a marker-based treatment policy, women with higher DFS rates with chemotherapy (marker-positive) would receive chemotherapy, whereas those with higher DFS rates without chemotherapy (marker-negative) would receive tamoxifen alone. The 5-year DFS rate of such a policy can be calculated by combining the average DFS rate among marker-positive women in the combined therapy group with the average DFS rate among marker-negative women in the tamoxifenonly group (Appendix). For marker C, modeled after the 21-gene recurrence score, the 5-year DFS rate under a marker-based treatment policy is 80% (CI, 78% to 82%). Of note, this is slightly higher than the 79% (CI, 78% to 82%) DFS rate achieved when all women receive tamoxifen plus chemotherapy, the current standard approach.
Proportion of Population Affected by Marker Measurement
Another key summary measure describes the proportion of women for whom treatment recommendations would change after marker measurement (25) . If knowledge of the marker values for all relevant patients does not change any treatment recommendations, then the marker is not useful. Referring to the Figure, we see that with marker C, the DFS rate is lower with adjuvant chemotherapy for 44% (CI, 20% to 60%) of women. These markernegative women would receive different treatment recommendations if the marker was measured than if it was not; without marker measurement, adjuvant chemotherapy would be recommended for all women. This measure describes the real effect of the marker in our example: Although use of marker C has a very small influence on the DFS rate, it dramatically reduces the number of women for whom adjuvant chemotherapy is recommended.
The interpretation of this measure of marker performance depends on the clinical context. In our breast cancer example, the treatment recommendations for markernegative women changed from tamoxifen plus chemotherapy to tamoxifen alone, allowing them to avoid the cost and toxicity of adjuvant chemotherapy. In this case, a marker associated with a higher proportion of patients with changed recommendations is better. If the standard of care were no chemotherapy, a marker associated with a lower proportion of patients with changed recommendations would be better, again to avoid unnecessary chemotherapy. In the context of 2 treatment options that are equally toxic, costly, or burdensome, the proportion of patients whose treatment recommendations change is less important for comparing the performance of candidate markers. In such a case, the key performance measure of interest would be the effect of the marker on the population response rate.
Measures for Comparing Markers
The aforementioned summary measures are particularly useful for comparing the performance of candidate treatment selection markers. Marker E is a better treatment selection marker than markers C or D, because it is associated with the highest DFS rate (95% [CI, 94% to 96%]) and the largest proportion of women who avoid adjuvant chemotherapy (45% [CI, 42% to 47%]) ( Table 1) . Marker D is not useful for selecting treatment, because women have higher DFS rates with the combined therapy at all marker values. Therefore, measuring marker D does not affect treatment recommendations or the DFS rate.
Although all 3 markers in Table 1 have strong interactions with treatment, they perform differently for treatment selection, as reflected by our measures. The magnitudes of their interactions also have little clinical relevance. For example, markers C and D both have interaction coefficients of 1.2 on the logit scale, which suggests that each percentile increase in these markers increases the odds ratio for treatment by e 1.2 , or 3.3-fold. However, this statistical interaction does not describe the population effect of using the markers to guide treatment decisions or the utility of the marker measurements to patients. Marker D is not useful for making treatment decisions (because all patients are classified as marker-positive), whereas marker C is useful.
Performance Measures for Binary Markers
Evaluation is simpler for markers that are inherently binary, such as markers of genetic mutations, because a positivity threshold is not needed. However, the measures of marker performance are the same. Table 2 shows this by using the binary marker G in our breast cancer example. Among marker-negative women, tamoxifen alone has a higher DFS rate than combined therapy (90% [CI, 88% to 92%] vs. 55% [CI, 51% to 59%]), whereas combined therapy has a higher DFS rate than tamoxifen alone for marker-positive women (95% [CI, 94% to 96%] vs. 67% [CI, 64% to 70%]). Describing these DFS rates is analogous to presenting marker-by-treatment predictiveness curves for a continuous marker. The proportion of patients affected by marker measurement is the proportion of marker-negative patients. For marker G, 1200 of 3000 or 40% (CI, 38% to 42%) of women are marker-negative and can avoid adjuvant chemotherapy. The overall DFS rate under a marker-based treatment policy is the DFS rate among marker-negative patients who receive tamoxifen alone combined with the DFS rate among marker-positive patients who receive combined therapy (93% [CI, 92% to 94%]). Using marker G to select treatment is therefore associated with a substantial increase in the DFS rate over the 79% (CI, 78% to 82%) rate achieved with current practice.
Effect of the Marker Distribution
The performance of a treatment selection marker is determined not only by the association between the marker and response to each treatment but also by the distribution of the marker. Two markers that have the same effect on the response rates to the 2 treatments (the same coefficient in a regression model for response) but different distributions will perform differently for treatment selection. For example, markers E and F in the Figure have the same association with DFS rate for each treatment (the same coefficient in the logistic regression model). However, marker E is normally distributed on the square-root scale and varies from 0 to 168, whereas marker F is uniformly distributed over the range 0 to 10. Marker E displays a greater variation in treatment effect as a function of marker value, leading to a higher DFS rate under a marker-based treatment policy (95% vs. 82% for marker F). Similarly, 2 markers with the same distribution but different associations with response to each treatment will perform differently. Markers C, D, and E, all of which have the same normal distribution on the square-root scale but different associations with DFS rate, illustrate this; these markers perform differently in terms of treatment selection. Marker-by-treatment predictiveness curves display both components of performance, the response rate as a function of marker value for each treatment and the distribution of the marker.
Randomized Versus Nonrandomized Designs
We recommend the setting of a randomized trial for marker evaluation for 2 reasons. The most important reason is that a randomized design allows for unbiased comparison of the response rates to the 2 treatments. In nonrandomized settings, such as an observational study or a comparison of a study of a single treatment with historical data, many factors may differ between treatment groups. If these factors are also associated with the response, they would confound the assessment of treatment effect. In addition, we use marker percentiles to align the 2 predictiveness curves. This facilitates making comparisons between markers measured on different scales, and allows us to determine the proportions of participants in different regions of the plot; however, the use of percentiles requires a welldefined population from which to determine the marker distribution. In a randomized trial, randomization generally ensures that the marker distribution is the same in the 2 treatment groups, and the marker distribution in the entire trial population can be used to calculate the percentiles. In a nonrandomized study, the observed marker distribution may differ between treatment groups and may not represent the distribution in any population of interest.
CONCLUSION
In conclusion, we propose an approach for evaluating treatment selection markers that involves plotting marker-by-treatment predictiveness curves, calculating measures of the overall improvement in outcome when the marker is used to guide treatment decisions, and determining the proportion of patients whose treatment decisions change with knowledge of their marker value. These calculations answer key clinical questions about how a marker can help patients choose treatment, how treatment decisions should be made on the basis of a continuous marker measurement, what effect using the marker to select treatment would have on the population, and what proportion of patients would have treatment changes on the basis of marker measurement. This approach improves upon current, nonstandardized approaches to marker evaluation, which have no inherent clinical meaning, and provides a framework for comparing markers. 
